EntreMed, Inc.: Survival Strategy in the Turbulent Biotech Industry

8,00 $50,00 $

CASE STUDY. EntreMed’s new management team needed to revise the overall company strategy to survive.

Effacer

Pour acheter une License d'enseignement, vous devez vous enregistrer et être approuvé par notre administration.

Description

EntreMed, Inc.: Survival Strategy in the Turbulent Biotech Industry: Abstract

This case presents the situation facing Neil Campbell, the newly promoted President & COO of EntreMed, Inc., at the beginning of 2003. EntreMed, a U.S. biotech company, was in crisis, with several million dollars of debt that had to be restructured and an unsustainable « burn » rate (annual expenditures). EntreMed’s new management team needed to revise the overall company strategy to survive. In crafting their new strategy, the team had to manoeuvre within a complex industry environment that included a complex new drug approval process, stringent protection of intellectual property rights, and a need to attract and retain top researchers.

Additional information

Teaching notes are available for teachers only. Contact the HEC Montréal Case Centre for more information.

Informations complémentaires

Année

Annexe

Éditeur

Format

Industrie

Institution

Langue

Licence

, ,

Nombre de pages

Notes pédagogiques

Numéro centre de cas

Parution

Taille

Avis

Il n’y a pas encore d’avis.

Soyez le premier à laisser votre avis sur “EntreMed, Inc.: Survival Strategy in the Turbulent Biotech Industry”